NCT07705555 Tiespectus Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07705555—A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07705555 is a hot trial to watch

Diabetic macular oedema is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07705555 is notable because it tests Tiespectus in a Phase 3 design while Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Year 1 serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment. Enrollment of 960 participants across the reported study geography shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Year 1 — Baseline and 1 Year
• Secondary: Mean Change in Central Subfield Thickness (CST) from Baseline to Week 52 — Baseline and Week 52
• Secondary: Mean Change in CST from Baseline Over Time — Up to approximately 2 years
• Secondary: Time to Absence of Diabetic Macular Edema (DME) at Week 52 — Up to approximately Week 52
• Secondary: Proportion of Participants with Absence of Intraretinal Fluid Over Time — Up to approximately 2 years

Benchmark readouts in the surrounding field

• Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy (Phase 2): Percent of Subjects With ≥ 2-step Improvement in Diabetic Retinopathy Severity Score (DRSS) = 41 Participants ; Percent of Subjects With ≥ 2-step Improvement in Diabetic Retinopathy Severity Score (DRSS) = 39 Participants
• COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY (Phase 3): BCVA(1 month) = 10.0 letters ; BCVA(1 month) = 8.0 letters
• A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe (Phase 3): Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS = 35 injections

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Tiespectus (Phase 3; Tie-2 x VEGF)

Company & Deal Intelligence context: Merck Sharp & Dohme LLC — http://www.merck.com.libproxy1.nus.edu.sg

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07705555 is a focused lens on Diabetic macular oedema development. Its value will be determined by whether Tiespectus can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.